GlassScriptPhysician profile
Lubna Jafri
NPI 1891456315
$2,052.79
in general payments reported to CMS, 2019-2025
11 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $288 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686 · Travel and Lodging: $308 · Education: $58.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.19 |
| Travel and Lodging | $308.11 |
| Education | $58.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $454.11 | 2025 | Infinity |
| Abbvie INC. | $356.69 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $345.32 | 2025 | Xeomin, Inbrija |
| Teva Pharmaceuticals USA, INC. | $198.49 | 2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $167.67 | 2024-2025 | Nuplazid |
| Insightec,INC | $145.84 | 2025 | Exablate |
| Biogen, INC. | $115.32 | 2024 | Skyclarys |
| Boston Scientific Corporation | $96.34 | 2025 | General - Dbs |
| Neurocrine Biosciences, INC. | $87.28 | 2025 | |
| Scilex Pharmaceuticals INC. | $67.73 | 2025 | |
| Amneal Pharmaceuticals LLC | $18.00 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lubna Jafri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.